A new study highlighted Monday the potential benefits of popular diabetes drugs on a wide range of health issues, including ...

A study by the Department of Veterans Affairs says that drugs like Ozempic can do plenty more than just help with weight loss ...

Viking (VKTX) is in the midst of a phase 2a dosing trial of its oral obesity drug VK2735, with a data readout expected in the second half of the year. The company is expected to launch a phase 3 trial ...

Compared with poor response, good response to obesity treatment was associated with lower risk of type 2 diabetes (adjusted ...

As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has ...

A new peer-reviewed study based on data from nearly 2M individuals highlights a wide range of clinical benefits and risks, ...

Adults with obesity receiving once-weekly semaglutide 7.2 mg lost a higher proportion of their body weight at 72 weeks than ...

Weight-loss and diabetes drugs reduced the risk of developing Alzheimer’s, an independent study published Monday showed.

Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...

UBS analyst Jo Walton maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK750.00. The company’s ...

The market for GLP-1 drugs is projected to exceed $200 billion in annual sales by 2031, according to Morningstar Equity ...

Novo Nordisk has faced a massive selloff in recent months amid disappointing drug trials and U.S. pressure to cut its prices.